Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
Hermanowski T, Kowalik E, Jakubczyk M, Niewada M
Record ID 32009100094
English
Authors' methods:
Economic evaluation
Details
Project Status:
Completed
URL for project:
http://aotm.gov.pl/assets/files/publikacje-prezentacje/09.05.06_PAH_Budget_Impact_Analysis.pdf
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Poland
MeSH Terms
- Antihypertensive Agents
- Costs and Cost Analysis
- Poland
- Epoprostenol
- Hypertension, Pulmonary
- Iloprost
- Vasodilator Agents
Contact
Organisation Name:
Agency for Health Technology Assessment and Tariff System
Contact Address:
Agency for Health Technology Assessment in Poland (AHTAPol), 22 Lotnik w Av., Warsaw, POLAND 02-668:Tel: +48 22 56 67 200 Fax: +48 22 56 67 202 Contact: Tomasz Garbaty
Contact Name:
sekretariat@aotm.gov.pl
Contact Email:
sekretariat@aotm.gov.pl
Copyright:
Agency for Health Technology Assessment in Poland (AHTAPol)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.